These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
475 related articles for article (PubMed ID: 33008420)
1. Cannabis, a cause for anxiety? A critical appraisal of the anxiogenic and anxiolytic properties. Sharpe L; Sinclair J; Kramer A; de Manincor M; Sarris J J Transl Med; 2020 Oct; 18(1):374. PubMed ID: 33008420 [TBL] [Abstract][Full Text] [Related]
2. Effect of prior foot shock stress and Δ Rock EM; Limebeer CL; Petrie GN; Williams LA; Mechoulam R; Parker LA Psychopharmacology (Berl); 2017 Jul; 234(14):2207-2217. PubMed ID: 28424834 [TBL] [Abstract][Full Text] [Related]
3. Female but not male rats show biphasic effects of low doses of Δ Salviato BZ; Raymundi AM; Rodrigues da Silva T; Salemme BW; Batista Sohn JM; Araújo FS; Guimarães FS; Bertoglio LJ; Stern CA Neuropharmacology; 2021 Sep; 196():108684. PubMed ID: 34181978 [TBL] [Abstract][Full Text] [Related]
4. Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug. Schier AR; Ribeiro NP; Silva AC; Hallak JE; Crippa JA; Nardi AE; Zuardi AW Braz J Psychiatry; 2012 Jun; 34 Suppl 1():S104-10. PubMed ID: 22729452 [TBL] [Abstract][Full Text] [Related]
5. Evaluating Potential Anxiolytic Effects of Minor Cannabinoids and Terpenes After Acute and Chronic Oral Administration in Rats. Jenkins BW; Moore CF; Covey D; McDonald JD; Lefever TW; Bonn-Miller MO; Weerts EM Cannabis Cannabinoid Res; 2023 Sep; 8(S1):S11-S24. PubMed ID: 37721993 [No Abstract] [Full Text] [Related]
6. THC, CBD, and Anxiety: A review of recent findings on the anxiolytic and anxiogenic effects of cannabis' primary cannabinoids. Lichenstein SD Curr Addict Rep; 2022 Dec; 9(4):473-485. PubMed ID: 38106452 [TBL] [Abstract][Full Text] [Related]
7. Acute and Extended Anxiolytic Effects of Cannabidiol in Cannabis Flower: A Quasi-Experimental Bidwell LC; Martin-Willett R; Skrzynski C; Lisano J; Ortiz Torres M; Giordano G; Hutchison KE; Bryan AD Cannabis Cannabinoid Res; 2024 Aug; 9(4):1015-1027. PubMed ID: 38252547 [No Abstract] [Full Text] [Related]
8. The anxiolytic effects of cannabinoids: A comprehensive review. Mallick K; Khan MF; Banerjee S Pharmacol Biochem Behav; 2024 Oct; 243():173828. PubMed ID: 39032530 [TBL] [Abstract][Full Text] [Related]
9. Cannabis containing equivalent concentrations of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) induces less state anxiety than THC-dominant cannabis. Hutten NRPW; Arkell TR; Vinckenbosch F; Schepers J; Kevin RC; Theunissen EL; Kuypers KPC; McGregor IS; Ramaekers JG Psychopharmacology (Berl); 2022 Nov; 239(11):3731-3741. PubMed ID: 36227352 [TBL] [Abstract][Full Text] [Related]
10. Subjective, behavioral and neurobiological effects of cannabis and cannabinoids in social anxiety. Rosário BDA; Lemes JA; de Lima MP; Ribeiro DA; Viana MB Rev Neurosci; 2024 Feb; 35(2):197-211. PubMed ID: 37812748 [TBL] [Abstract][Full Text] [Related]
11. A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice. Long LE; Chesworth R; Huang XF; McGregor IS; Arnold JC; Karl T Int J Neuropsychopharmacol; 2010 Aug; 13(7):861-76. PubMed ID: 19785914 [TBL] [Abstract][Full Text] [Related]
12. Using the BMD Approach to Derive Acceptable Daily Intakes of Cannabidiol (CBD) and Tetrahydrocannabinol (THC) Relevant to Electronic Cigarette Liquids. Hindelang P; Scharinger A; Richling E; Walch SG; Lachenmeier DW Front Biosci (Landmark Ed); 2022 Jul; 27(8):228. PubMed ID: 36042166 [TBL] [Abstract][Full Text] [Related]
13. Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis. Black N; Stockings E; Campbell G; Tran LT; Zagic D; Hall WD; Farrell M; Degenhardt L Lancet Psychiatry; 2019 Dec; 6(12):995-1010. PubMed ID: 31672337 [TBL] [Abstract][Full Text] [Related]
14. Effects of ∆ Raymundi AM; da Silva TR; Sohn JMB; Bertoglio LJ; Stern CA BMC Psychiatry; 2020 Aug; 20(1):420. PubMed ID: 32842985 [TBL] [Abstract][Full Text] [Related]
15. Evidence for Use of Cannabinoids in Mood Disorders, Anxiety Disorders, and PTSD: A Systematic Review. Stanciu CN; Brunette MF; Teja N; Budney AJ Psychiatr Serv; 2021 Apr; 72(4):429-436. PubMed ID: 33530732 [TBL] [Abstract][Full Text] [Related]
16. The Potential of Cannabidiol Treatment for Cannabis Users With Recent-Onset Psychosis. Hahn B Schizophr Bull; 2018 Jan; 44(1):46-53. PubMed ID: 29083450 [TBL] [Abstract][Full Text] [Related]
18. A randomised controlled trial of vaporised Δ Solowij N; Broyd S; Greenwood LM; van Hell H; Martelozzo D; Rueb K; Todd J; Liu Z; Galettis P; Martin J; Murray R; Jones A; Michie PT; Croft R Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):17-35. PubMed ID: 30661105 [TBL] [Abstract][Full Text] [Related]
19. Cannabidiol in medical marijuana: Research vistas and potential opportunities. Rong C; Lee Y; Carmona NE; Cha DS; Ragguett RM; Rosenblat JD; Mansur RB; Ho RC; McIntyre RS Pharmacol Res; 2017 Jul; 121():213-218. PubMed ID: 28501518 [TBL] [Abstract][Full Text] [Related]
20. Sex-Dependent Synergism of an Edible THC: CBD Formulation in Reducing Anxiety and Depressive-like Symptoms Following Chronic Stress. Pérez-Valenzuela E; Hudson R; Uzuneser T; De Felice M; Szkudlarek H; Rushlow W; Laviolette SR Curr Neuropharmacol; 2024; 22(12):2059-2078. PubMed ID: 37702237 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]